Cancer is a disease for which there remains a great unmet medical need, and therefore the discovery and development of new antineoplastic agents is critically important. The present invention relates in part to new therapeutic compounds with antineoplastic activity. Provided herein are polyamine sulfonamides such as compounds of Formula (I), or pharmaceutically acceptable salts thereof, which may be used in the treatment and/or prevention of diseases such as cancer. Also provided herein are pharmaceutical compositions and kits comprising the inventive compounds. Furthermore, the present invention provides methods of treating and/or preventing diseases (e.g., cancer) using compounds of Formula (I), or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof. Other methods provided include methods for inducing apoptosis of a cell, as well as methods for inhibiting alpha-enolase enzymatic activity in vivo and in vitro.

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001## wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Compounds of the formula I:

##STR00001## or a pharmaceutical salt thereof, wherein p, s, A, R.sup.3 and R.sup.e are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

The invention relates to an organic molecule having a structure of the formula I

##STR00001##

where X=CN or CF.sub.3; D=chemical unit having a structure of the formula I-1:

##STR00002##

where #=attachment point of the unit of formula I-1 to the central phenyl ring in the structure of formula I; A and B=independently of one another selected from the group consisting of CRR.sup.1, CR, NR, N, there being a single or double bond between A and B and a single or double bond between B and Z; Z=a direct bond or a divalent organic bridge which is a substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group or a combination thereof, CRR.sup.1, CCRR.sup.1, CNR, NR, O, SiRR.sup.1, S, S(O), S(O).sub.2, O-interrupted substituted or unsubstituted C1-C9-alkylene, C2-C8-alkenylene, C2-C8-alkynylene or arylene group, phenyl units or substituted phenyl units.

The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

The present invention relates to compounds capable of modulating the activity of the cellular prion protein (PrPC) and their use for the treatment of immune and neurodegenerative diseases.

The present invention relates to compounds capable of modulating the activity of the cellular prion protein (PrPC) and their use for the treatment of immune and neurodegenerative diseases.